Use of Ebola Vaccine: Expansion of Recommendations of the Advisory Committee on Immunization Practices to Include two Additional Populations — United States, 2021

Jason H. Malenfant, MD; Allison Joyce, MSc; Mary J. Choi, MD; Caitlin M. Cossaboom, DVM, PhD; Amy N. Whitesell, MPH; Brian H. Harcourt, PhD; Robert L. Atmar, MD; Julie M. Villanueva, PhD; Beth P. Bell, MD; Christine Hahn, MD; Jamie Loehr, MD; Richard T. Davey, MD; Armand Sprecher, MD; Colleen S. Kraft, MD; Trevor Shoemaker, PhD; Joel M. Montgomery, PhD; Rita Helfand, MD; Inger K. Damon, MD, PhD; Sharon E. Frey, MD; Wilbur H. Chen, MD


Morbidity and Mortality Weekly Report. 2022;71(8):290-292. 

In This Article


Preexposure vaccination with ERVEBO is now also recommended for adults aged ≥18 years in the U.S. population who are at high risk for potential occupational exposure to Ebola virus:

  • Health care personnel involved in the care and transport of patients with suspected or confirmed EVD at SPTCs, or

  • Laboratorians and support staff members at LRN facilities that handle specimens that might contain replication-competent Ebola virus (species Zaire ebolavirus) in the United States.